ReviewMicrobial biotechnology2014
Discovering new bioactive molecules from microbial sources.
Review in Microbial biotechnology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed.
- Article
- Role of the Plant-Microbiome Partnership in Environmentally Harmonious 21st Century Agriculture.Microorganisms · 2025Review
- Microtiter Plate Cultivation Systems Enable Chemically Diverse Metabolic Footprints During Bacterial Natural Product Discovery.Biotechnology and bioengineering · 2025Article
- Genome mining reveals the biosynthetic potential of a novel Lysinibacillus zambalensis sp. nov., isolated from a hyperalkaline spring.Archives of microbiology · 2025Article
- Process optimization and extraction of alkaline protease from halotolerant Streptomyces sp. VITGS3 and its use as a contact lens cleaner.Journal, genetic engineering & biotechnology · 2025Article
- A Review of the Biotechnological Potential of Cave Fungi: A Toolbox for the Future.Journal of fungi (Basel, Switzerland) · 2025Review
- Article
- Implications for the role of natural products in Parkinson disease therapy.Archives of medical science : AMS · 2025Article
- Impact of growth conditions on the abundance and diversity of cultivable bacteria recovered fromFEMS microbes · 2025Article
- ScreeningOpen research Europe · 2025Article
- Genome Mining Analysis Uncovers the Previously Unknown Biosynthetic Capacity for Secondary Metabolites in Verrucomicrobia.Marine biotechnology (New York, N.Y.) · 2024Article
- Article
- Heterologous Expression of Type II PKS Gene Cluster Leads to Diversified Angucyclines inMarine drugs · 2024Article
- CLOCI: unveiling cryptic fungal gene clusters with generalized detection.Nucleic acids research · 2024Article
- Antifungal, antiaflatoxigenic, and cytotoxic properties of bioactive secondary metabolites derived from Bacillus species.Scientific reports · 2024Article
- Cryosphere: a frozen home of microbes and a potential source for drug discovery.Archives of microbiology · 2024Review
- Secondary metabolites with antimicrobial activity produced by thermophilic bacteria from a high-altitude hydrothermal system.Frontiers in microbiology · 2024Article
- Induction of Fungal Secondary Metabolites by Co-Culture with Actinomycete Producing HDAC Inhibitor Trichostatins.Journal of microbiology and biotechnology · 2023Article
- Heterologous Production and Biosynthesis of Threonine-16:0dioic acids with a Hydroxamate Moiety.Journal of natural products · 2023Article
- Harnessing the Potential of Biosurfactants for Biomedical and Pharmaceutical Applications.Pharmaceutics · 2023Review
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is an increased need for new drug leads to treat diseases in humans, animals and plants. A dramatic example is represented by the need for novel and more effective antibiotics to combat multidrug-resistant microbial pathogens. Natural products represent a major source of approved drugs and still play an important role in supplying chemical diversity, despite a decreased interest by large pharmaceutical companies. Novel approaches must be implemented to decrease the chances of rediscovering the tens of thousands of known natural products. In this review, we present an overview of natural product screening, focusing particularly on microbial products. Different approaches can be implemented to increase the probability of finding new bioactive molecules. We thus present the rationale and selected examples of the use of hypersensitive assays; of accessing unexplored microorganisms, including the metagenome; and of genome mining. We then focus our attention on the technology platform that we are currently using, consisting of approximately 70,000 microbial strains, mostly actinomycetes and filamentous fungi, and discuss about high-quality screening in the search for bioactive molecules. Finally, two case studies are discussed, including the spark that arose interest in the compound: in the case of orthoformimycin, the novel mechanism of action predicted a novel structural class; in the case of NAI-112, structural similarity pointed out to a possible in vivo activity. Both predictions were then experimentally confirmed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.